Saturday - March 7, 2026
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
February 17, 2026
SOUTH SAN FRANCISCO, California, Feb. 17 -- Genentech, a member of Roche Group, issued the following news release on Feb. 15, 2026:

* * *

Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease

MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years

Up to 30% of people w . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products